other material
confidence high
sentiment positive
materiality 0.75
Monte Rosa's MRT-8102 cuts hsCRP 85%, Lp(a) 24% in GFORCE-1 Phase 1; three Phase 2 trials planned
Monte Rosa Therapeutics, Inc.
- GFORCE-1 enrolled 108 obese subjects at elevated CVD risk; MRT-8102 at 5, 20 or 40 mg once daily achieved a median NEK7 reduction of ~80-90% across all three dose levels over 4 weeks of dosing.
- Median biomarker reductions: hsCRP -85%, calprotectin -56%, IL-6 -54%, SAA -51%, S100A12 -46%, fibrinogen -28%; HMGB1 -40% and IL-1β -37% in top-quartile subjects; lipoprotein(a) -24%.
- No serious adverse events reported; TEAEs in 33% of MRT-8102 subjects vs 30% on placebo, no evidence of increased infection risk, and no increases in LDL-C or triglycerides (unlike IL-6(R) blockade).
- Phase 2b GFORCE-2 in stable coronary artery disease + residual inflammation expected H1 2027; GEMINI-1 in gout Q4 2026/Q1 2027 with data H2 2027; GALAXY-1 in hidradenitis suppurativa H1 2027.
- Elevated baseline DAMPs and IL-1β clustered in carriers of NLRP3 risk alleles (~30% of the GFORCE-1 population), supporting a genetically enrichable higher-risk development population.